Meeting
2018 ASCO Annual Meeting
Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.
Authors
Steven G. DuBois
Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center, Boston, MA
Steven G. DuBois , Brenda Weigel , Theodore Willis Laetsch , Margaret Macy , Donna Elise Levy , Gary Mo , Jennifer A. Wright , Leo Mascarenhas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02677116
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10541)
DOI
10.1200/JCO.2018.36.15_suppl.10541
Abstract #
10541
Poster Bd #
214
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase 1, open-label, dose-escalation study of olaratumab as a single agent and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors.
First Author: Leo Mascarenhas
Poster
2014 ASCO Annual Meeting
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
First Author: Holly Jane Meany
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
First Author: Stuart Cramer